Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial
Therapeutic Advances in Psychopharmacology September 1, 2025 Sally Meikle, Olivia Carter, Paul Liknaitzky et al. 2 citations
In an open-label pilot trial, two 25 mg doses of psilocybin combined with psychotherapy produced a clinically meaningful reduction in depressive symptoms at 3 weeks in people with treatment-resistant depression. The average improvement was sustained at 20 weeks, but individual responses varied: two participants showed lasting benefit, three relapsed, and two did not improve. Mindset before dosing, spiritual experiences, and perceptual changes during the session predicted treatment trajectory, whereas treatment expectations did not. No serious adverse events occurred. The findings support further research into tailoring psilocybin therapy to individual variability.